<DOC>
	<DOCNO>NCT01563718</DOCNO>
	<brief_summary>Naltrexone medication show help prevent relapse opioid addiction report clinically effective parolee population although rarely use . Recently depot formulation one-month duration receive FDA approval treatment alcoholism opiate dependence . This mean rather take medication daily , individual receive one injection last approximately 30 day . The purpose study determine whether monthly injection naltrexone practical useful prevention relapse opioids re-incarceration administer inmates prior release prison . The investigator also monitor HIV risk behavior determine whether intervention reduces risky behavior associate intravenous drug abuse spread virus HIV hepatitis C. Volunteers randomize receive injection depot naltrexone prior release prison contact study personnel community follow release . Participants assign receive naltrexone prison receive 1 injection prison , 5 additional monthly injection 5 month upon release . Participants assign contact study personnel upon release receive 6 injection community RIH release ACI . Patients group give identical follow monthly six month include measure opiate use self-report , urine test . An additional scheduled urine test take place month monthly visit . There also 12-month follow-up period participant group , consist 2 visit , space 6 month apart , mean participant enrol study total 18 month . All participant ask complete brief questionnaire follow-up visit ass thing service receive , drug use , depression .</brief_summary>
	<brief_title>Pre-Release VIVITROL Opioid Dependent Inmates</brief_title>
	<detailed_description />
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Incarcerated adult know release date . 2 . Meet DSMIV criterion current ( and/or prior incarceration ) opioid dependence . 3 . Not interested agonist ( methadone , buprenorphine ) treatment . 4 . Currently opioid free history ( 'detoxed ' ) , negative urine opioids sign opiate withdrawal IV ( IM available venous access ) injection 0.8 mg naloxone . 5 . Good health medical history , physical examination laboratory test . 6 . Age old 18 . 7 . Understands sign consent form . 8 . Able speak understand English . 9 . Females : pregnant ( urine hCG negative baseline prior injection ) , plan conception ; plan appropriate contraception sexually active . 1 . Current drug alcohol dependence require long term residential treatment would interfere outpatient study participation . Dependence substances commonly cooccur opioid dependence ( e.g . cocaine , cannabis , alcohol ) rise level severity exclusionary order achieve maximally representative sample . 2 . Liver failure and/or liver function test level great three time normal . 3 . Pregnancy , lactation , failure use adequate contraceptive method ; 4 . Active medical illness might make participation hazardous , e.g . untreated hypertension , hepatitis AST ALT &gt; 3 time upper limit normal , unstable diabetes heart disease . Adequately treated medical condition acceptable . 5 . Untreated psychiatric disorder might make participation hazardous , e.g . untreated psychosis , bipolar disorder mania , significant suicide risk . Adequately treated psychiatric disorder appropriate psychotropic medication would allow . 6 . History allergic reaction naltrexone ; 7 . Current chronic pain diagnosis opioids require pain relief . 8 . Obesity ( BMI 40 great ) reduce likelihood injection site reaction . 9 . Known intolerance and/or hypersensitivity naltrexone , carboxymethylcellulose , polylactidecopolymers ( PLG ) components diluent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>